The Medical Device Business Journal — Medical Device News & Articles | MassDevice
ZimVie (Nasdaq: ZIMV) saw declining revenue and widening losses during its first full quarter independent of Zimmer Biomet.
The company also reported yesterday evening that it is reducing full-year guidance. ZIMV shares are down more than 11% to $17.56 apiece this morning on the news. MassDevice‘s MedTech 100 Index, which includes stocks of the world’s largest medical device companies, is up more than 3%.
CEO Vafa Jamali told MassDevice and Medical Design & Outsourcing on March 1 — ZimVie’s first day of public trading — that initial tasks in the company’s spine tech business included pulling out of countries that had proved unprofitable. There were also some spine product discontinuations.
Coupled with a strong U.S. dollar causing headwinds for the dental tech side of the business, ZimVie’s losses roughly doubled year-over-year to $8.7 million, or 33¢ per share, for the quarter ended June 30, 2022. Sales were down 11.5% year-over-year to $233.4 million.
ZimVie reported adjusted EPS of 67¢. Yahoo Finance presently lists one analyst revenue prediction for the quarter who expected $238.3 million in sales.
“We continue to make progress towards our most vital commercial initiatives in both our dental and spine segments” Jamali said in a news release out after market close. “Within dental, we recently launched two highly innovative products: the T3 PRO tapered implant and the Encode emergence healing abutment. Within spine, we received a major positive insurance policy decision from Anthem Blue Cross Blue Shield for The Tether, a device for treatment of pediatric scoliosis, expanding insurance coverage for up to 30 million lives.”
Jamali added: “We are also tracking to our plan to improve the short- and long-term operational efficiency of our newly independent company.”
Facing greater than anticipated foreign exchange headwinds, ZimVie is reducing its full-year revenue forecast to $915 to $930 million versus prior guidance of $1 billion.
The company is also cutting its adjusted EPS guidance to $2.10 to $2.30 from a previous $1.80 to $2.00 amid lower sales.
This story originally ran on Aug. 10, 2022. Updated Aug. 11 with the next-day stock price.
Filed Under: Business/Financial News, Dental, Featured, MassDevice Earnings Roundup, News Well, Orthopedics, Spine, Wall Street Beat Tagged With: ZimVie
Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.